BY: Dopine

Novo Nordisk Liraglutide continues to make efforts in China, its second indication application to be approved soon.

On April 30th, the application of Novo Nordisk Liraglutide Injection (Trade name: Novozymes) (the acceptance number is JXSS1800030) in the NMPA changed to "in approval", it is speculated that the indication applied for the liraglutide is to reduce the risk of cardiovascular events in patients with type 2 diabetes.

Liraglutide (Trade name: Victoza) is a glucagon-like peptide-1 (GLP-1) analog developed by Novo Nordisk. It was approved by the FDA in 2010 for the treatment of adult patients with type 2 diabetes. In 2017, Victoza was approved by the FDA to reduce the risk of heart attack, stroke and cardiovascular death in patients with type 2 diabetes. In June 2019, it was approved by the FDA to expand the indications for the treatment of patients with type 2 diabetes over 10 years of age.

As of now, Victoza has been approved in more than 100 countries around the world, treating more than 1.2 million patients with type 2 diabetes. Since its marketing, liraglutide's global sales have increased year by year and reached its peak sales in 2018, approximately DKK 24333 million.

In 2011, liraglutide was approved in China under the trade name Victoza. However, due to the high price, Victoza's  sales in China are not optimistic. In July 2017, Victoza has successfully entered the medical insurance catalogue through negotiations, and sales have continued to rise. In 2018, Victoza's sales increased by 73% to DKK 521 million, accounting for 87% of the GLP-1 market in China and 1.3% of the entire diabetes market.

Novo Nordisk successfully renewed the Chinese medical insurance for 2019, and the Chinese liraglutide market is still exclusively owned by the Novo Nordisk family. It is expected that with the approval of a second indications in the future, liraglutide is expected to usher in a new high in sales.

-----------------------------------------------------------------------
Editor's Note:

To become a freelance writer of En-CPhI.CN,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@imsinoexpo.com.